-
Document de presse | 2016.07.18
Malaria: a genetically attenuated parasite induces an effective, long-lasting immune response
With nearly 3.2 billion people currently at risk of contracting malaria, scientists from the Institut Pasteur, the CNRS and Inserm have experimentally developed a live, genetically attenuated vaccine for Plasmodium, the parasite responsible for the disease. By identifying and deleting one of the parasite's genes, the scientists enabled it to induce an effective, long-lasting immune response...
-
Document de presse | 2016.08.02
Tuberculosis: a promising vaccine candidate
Scientists from the Institut Pasteur, working in collaboration with a team from Italy, have published the results of their research into the action mechanisms of a promising experimental tuberculosis (TB) vaccine in the journal PLOS Pathogens. BCG, the only currently approved TB vaccine, has been around for almost a century, but it is only partially effective and the protection it offers fades...
-
Document de presse | 2016.08.29
Alzheimer's: nicotinic receptors as a new therapeutic target
Several scientific studies have indicated that nicotine may be beneficial for memory function. Scientists from the Institut Pasteur and the CNRS set out to shed further light on the properties attributed to nicotine – which is known to have an adverse effect on health – by determining the precise structure of the nicotinic receptors in the hippocampus region of the brain. Using mouse...
-
Document de presse | 2015.01.13
Identification of an Achilles heel in the dengue virus gives new hope for vaccine development
In association with Imperial College London, scientists at the Institut Pasteur and CNRS have identified a vulnerable site on the surface of the dengue virus which is targeted by the only broadly neutralizing antibodies identified to date. This discovery offers a new target for the development of a vaccine to combat all four types of dengue virus currently in circulation. These results were...
-
Document de presse | 2015.01.15
The biological basis of good health
In a biological sense, what does it mean to be “in good health”? This far-reaching question is the focus of the “Laboratoire d'Excellence” project Milieu Intérieur (“Environment Within”), coordinated at the Institut Pasteur by Professor Matthew Albert (Dendritic Cell Immunobiology Unit, Institut Pasteur/Inserm) and Dr. Lluis Quintana-Murci (Human...
-
Document de presse | 2015.01.22
Ebola: Study of the chains of transmission in Conakry
Researchers at the Institut Pasteur of Dakar and the Institut Pasteur in Paris have reconstructed chains of transmission of Ebola virus in the capital city of Guinea, from February to August 2014. The data show the positive impact of control measures on the evolution of the epidemic but highlight the challenges of Ebola control in large urban centres. The study is published in The Lancet...
-
Document de presse | 2015.01.26
Patronage: the Institut Pasteur and the Total Foundation renew their common commitment against infectious diseases
For 10 years, Total and its corporate foundation working alongside the Institut Pasteur and its International Network in the fight against infectious diseases. A new sponsorship agreement, of EUR 6 million for three years, was signed on 26 January 2015. It will provide funding, for public health and research projects in resource limited countries in order to better understand the therapeutic and...
-
Document de presse | 2015.02.02
Moderna and Institut Pasteur Sign Strategic Research Collaboration
Research partnership will advance the development of mRNA vaccines and passive immunity therapies for infectious diseases. Press releaseCAMBRIDGE, Mass. (USA) and Paris (France), Feb. 3rd, 2015 Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ and the Institut Pasteur, a recognized public benefit organization with three core missions -...
-
Document de presse | 2015.03.01
Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases
Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability. Themis Bioscience (‘Themis’), a biotechnology company developing innovative prophylactic vaccines for emerging tropical infections, and the Institut Pasteur, an international...
-
Document de presse | 2015.03.02
Dr. Jean-François Chambon is appointed Vice-President Communications and Fundraising at the Institut Pasteur
On February 2, 2015, Dr. Jean-François Chambon took up the post of Vice-President Communications and Fundraising at the Institut Pasteur. Dr. Chambon is also a member of the Executive Board. He is responsible for promoting the Institut Pasteur's visibility among its stakeholders in France and across the world, a key factor in the success of its 2015-2018 strategic plan to tackle the...
